News
We send the latest information from SMC Laboratories.
What is the best non-clinical liver cancer model with 100% cancer incidence rate and suitable for liver cancer assessment?
If you are considering a drug evaluation study for liver cancer using a mouse model, our STAM™-HCC/IO⁺ model best replicates the pathology and characteristics seen in human patients with liver cancer, which allows for the optimal evaluation of your compound's efficacy. In addition to molecular targeted drugs such as lenvatinib and sorafenib, immune checkpoint…
The [optimal disease model] that maximizes your research outputs.
The bleomycin-induced pulmonary fibrosis mouse model is commonly used to replicate the pathogenesis of IPF in humans. If you are considering using a mouse model of pulmonary fibrosis for drug evaluation studies, then using a suitable study design allows you to best evaluate the efficacy of your compound. As mentioned in a previous news,…
【Case Study】Why do disease model mice change the outcomes?
If you are considering using a lung fibrosis model in a drug efficacy study, you can maximize the efficacy of your compound by using a disease induction model that is appropriate for your evaluation, rather than using a standard pathological model. Today, we will provide a clear overview of the disease induction periods in…
Introduction of [Pathway MAP of MASH compounds] to accelerate your research
When conducting non-clinical research, it is important to choose an appropriate mouse model that reproduces human pathology and also allows your compound to be evaluated. In this post you will find the appropriate model mouse for your compound and the results. As a pioneer in the field of MASH/NASH, we have conducted more…
Preclinical COPD study with positive controls, Roflumilast
Today, we share an update regarding new preclinical service. It is now possible to use a positive control (Roflumilast) in a drug efficacy evaluation study using PPE-induced COPD model. The drug used as a positive control is roflumilast, a PDE-4 inhibitor. Mean linear intercept by histological analysis of the lungs, the primary endpoint…
Introduction of Chronic Kidney Disease Mice Models
I am writing you today to share some information on our chronic kidney disease (CKD) models. CKD is a condition that is characterized by abnormalities in the structure or function of the kidneys. It is a global public health problem and causes a rising incidence and prevalence of kidney failure with poor outcomes. However,…
Cholangiocarcinoma and Primary sclerosing cholangitis
On February 15, World Cholangiocarcinoma Day! Today we would like to introduce cholangiocarcinoma (CCA, bile duct cancer) and its risk factor, primary sclerosing cholangitis (PSC). CCA is the second most common liver cancer after hepatocellular carcinoma, and its incidence appears to be increasing worldwide (Banales JM et al., Nat Rev Gastroenterol Hepatol. 2020)….
Press Release Regarding STAM-HCC/IO+ Mice has been distributed.
We are pleased to announce that our STAM(TM)-HCC/IO+ mouse was introduced in PR Newswire (Kyodo News JBN). For details, please refer to the following URL. SMC Laboratories Reveals Innovative STAM™-HCC/IO+ Mouse for Identifying and Developing Novel Therapeutic Drugs for Liver Cancer, Blazing a Trail in the Immuno-Oncology Field URL ► https://kyodonewsprwire.jp/release/202402076294 …
Study published in Sci Transl Med. on the effects of A monoclonal antibody targeting nonjunctional claudin-1 in CKD of UUO model.
We introduce a case study of drug efficacy evaluation of anti-claudin-1 antibody using our chronic kidney disease model, UUO model. Title: A monoclonal antibody targeting nonjunctional claudin-1 inhibits fibrosis in patient-derived models by modulating cell plasticity ( Roehlen et al., Sci Transl Med. 2022 ) Article Link ► [DOI: 10.1126/scitranslmed.abj4221] In this study, we administered…
Announcement of webinar 【MASH-Liver cancer model mouse_Pharmacology study for MASH/fibrosis targeting GLP-1】
Today, we are excited to invite you to join our Webinar that will be taking place on January 25th from 9:30 AM (JST). In this webinar, we will introduce the drug evaluation study with GLP-1. That is why we highly recommend that you join our free webinar! Webinar Link ►►► Click here …